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Cholesterol Crystal Embolization
                                                
 Cutaneous pseudovasculitis represents a di-
verse spectrum of disorders that might clinically 
mimic cutaneous vasculitis and can be broadly 
classified into diseases that produce hemorrhage 
or vessel occlusion (1). Pigmented purpuric der-
matitis, scurvy, senile purpura, idiopathic thrombo-
cytopenic purpura, and viral or drug induced erup-
tions are some of the pseudovasculitic disorders 
that are the result of dermal hemorrhage due to 
vessel wall incompetence. Apart from the above 
mentioned disorders, diseases like cholesterol 
embolism, antiphospholipid syndrome, thrombotic 
thrombocytopenic purpura or livedo vasculopathy 
cause vascular injury due to infarction secondary 
to luminal occlusion (livedo, cyanosis, ulcers, digi-
tal necrosis) (1). Skin biopsy, as a crucial step in 
making the correct diagnosis, allows separation 
of these entities from true vasculitis. A histological 
hallmark of cutaneous vasculitis is the presence 
of inflammatory infiltrate within or around the ves-
sel walls accompanied by fibrin deposition (fibri-
noid necrosis) (2). The lack of histologic criteria 
required for the diagnosis of authentic vasculitis 
should always direct evaluation and diagnosis to-
wards pseudovasculitis. Cholesterol crystal em-
bolization, as one of these vasculitis mimics, is a 
severe complication of atherosclerosis originating 
from ulcerated atherosclerotic plaques of the aorta 
or its major branches (3). Since its first descrip-
tion in 1945, it has been described in almost every 
major organ system, often mimicking multisys-
temic disease resembling systemic vasculitis and 
being underdiagnosed as leading to multiorgan 
failure and death (4). It can occur spontaneously 
or following invasive vascular procedures, anti-
coagulant and thrombolytic therapies. When an 
atheromatous plaque is disrupted, its components 
are released into the bloodstream occluding small 
arterioles. Clinical manifestations, mostly those of 
renal and skin involvement, reflect ischemia of the 
affected organs. The kidney, because of its prox-
imity to the aorta and direct blood supply from that 
vessel, is the main target organ with progressive 
renal failure developing in almost all patients af-
fected (4,5). Livedo reticularis is usually the first 
and most common sign of skin involvement, al-
though cyanosis, ulceration and gangrene might 
be seen as well (6,7). Livedo is generally bilateral, 
involving legs and feet. Examination of the patient 
in upright position has been suggested to increase 
the likelihood of detecting it. Some reports point to 
the fact that it can be missed when examining the 
patient while lying down (6). The timing of clini-
cal findings varies from days (sometimes hours) to 
weeks. Demonstration of cholesterol clefts in deep 
dermal vessels from areas of livedo reticularis in 
skin biopsies is a prerequisite for the diagnosis. 
Histologically, initial lesions can be associated 
with perivascular infiltrate of leukocytes, lympho-
cytes and eosinophils, whereas older lesions will 
have multinucleated giant cells and fibrosis of the 
vessel wall (1). There still are no standard treat-
ment modalities for cholesterol embolization. 
Corticosteroids have been proposed by some au-
thors while others stand for pentoxifylline and the 
statins, which stabilize cholesterol-rich plaques 
and prevent recurrence of cholesterol emboliza-
tion (7). 
 We might expect that the prevalence of the 
aforementioned disease will increase because 
the incidence of atherosclerotic disease is higher 
daily, and interventional procedures as well as an-
ticoagulation therapy are being ever more widely 
used. Cholesterol embolization should be taken in 
consideration on the differential diagnosis of ne-
crotic skin lesions or livedo reticularis in patients 
having undergone invasive vascular interventions, 
anticoagulant therapies, or in those with acute re-
nal failure.
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